| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Lucidenic acid LM1 targets various signaling pathways involved in inflammation and cancer. It may inhibit the activation of NF-κB and reduce the expression of pro-inflammatory cytokines. It may also induce apoptosis in cancer cells through the mitochondrial pathway and inhibit cell proliferation. The compound may modulate the PI3K/Akt and MAPK signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, lucidenic acid LM1 has been shown to inhibit the growth of various cancer cell lines and induce apoptosis. It may also have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and inhibiting the activation of NF-κB. The compound can modulate signaling pathways such as MAPK and PI3K/Akt.
|
| ln Vivo |
In vivo, lucidenic acid LM1 has been studied in animal models of inflammation and cancer. It may have anti-tumor effects in xenograft models and anti-inflammatory effects in models of inflammation. Its pharmacokinetics and bioavailability are areas of active research.
|
| Enzyme Assay |
For non-cellular enzyme assays, lucidenic acid LM1 can be tested for inhibition of enzymes such as COX-2, iNOS, and MMPs using standard enzyme activity assays. It can also be tested for antioxidant activity using DPPH, ABTS, or FRAP assays.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines and inflammatory cell models are cultured and treated with lucidenic acid LM1. Cell proliferation, apoptosis, and inflammatory marker expression are assessed using MTT assays, flow cytometry, ELISA, and Western blotting. Signaling pathway activation is assessed using phospho-specific antibodies.
|
| Animal Protocol |
For in vivo animal studies, lucidenic acid LM1 can be administered orally or intraperitoneally to animal models of disease. Inflammation models and cancer models can be used. Inflammatory markers, tumor growth, and survival are assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of lucidenic acid LM1 include solubility in DMSO and ethanol. It is a lipophilic compound and may have poor oral bioavailability. It is metabolized in the liver and excreted.
|
| Toxicity/Toxicokinetics |
As a natural product from Ganoderma lucidum, lucidenic acid LM1 is generally considered safe at low doses. No significant toxicity has been reported in preclinical studies.
|
| Additional Infomation |
Lucidenic acid N is a tetracyclic triterpenoid compound with the structure 25,26,27-trinorlanster-8-en-24-acid, substituted with hydroxyl groups at positions 3 and 7, and with carbonyl groups at positions 11 and 15 (3β, 5α, 7β stereoisomers). It was isolated from the fruiting body of Ganoderma lucidum and exhibits cytotoxicity against tumor cells. Lucidenic acid N can function as a metabolite, an EC 3.1.1.8 (cholinesterase) inhibitor, and an antitumor drug. It is a tetracyclic triterpenoid compound, a cyclic terpene ketone, a dioxomonocarboxylic acid, and a secondary alcohol. Lucidenic acid N has been reported in bovine plants and Ganoderma lucidum, and relevant data are available.
Lucidenic acid LM1 is a naturally occurring triterpenoid from Ganoderma lucidum. It has anti-inflammatory and anti-tumor activities. It may inhibit NF-κB signaling and induce apoptosis in cancer cells. It is a bioactive constituent of the medicinal mushroom Reishi. |
| Molecular Formula |
C27H40O6
|
|---|---|
| Molecular Weight |
460.6029
|
| Exact Mass |
460.282
|
| CAS # |
364622-33-3
|
| PubChem CID |
21592283
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
640.7±55.0 °C at 760 mmHg
|
| Melting Point |
202-204 °C
|
| Flash Point |
355.3±28.0 °C
|
| Vapour Pressure |
0.0±4.3 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
2.55
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
933
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCC(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)C
|
| InChi Key |
YBGBNHHXOJXFNM-UQCMLMITSA-N
|
| InChi Code |
InChI=1S/C27H40O6/c1-14(7-8-21(32)33)15-11-20(31)27(6)23-16(28)12-18-24(2,3)19(30)9-10-25(18,4)22(23)17(29)13-26(15,27)5/h14-16,18-19,28,30H,7-13H2,1-6H3,(H,32,33)/t14-,15-,16+,18+,19+,25+,26-,27+/m1/s1
|
| Chemical Name |
(4R)-4-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1711 mL | 10.8554 mL | 21.7108 mL | |
| 5 mM | 0.4342 mL | 2.1711 mL | 4.3422 mL | |
| 10 mM | 0.2171 mL | 1.0855 mL | 2.1711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
